SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 13, 1999
DURAMED PHARMACEUTICALS, INC.
______________________________________________________
(Exact name of registrant as specified in its charter)
Delaware 0-15242 11-2590026
_______________________________________________________
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identifi-
incorporation) cation No.)
7155 East Kemper Road, Cincinnati, Ohio 45249 (513) 731-9900
_____________________________________________________________
(Address and telephone number, including area code, of
principal executive offices)
INFORMATION TO BE INCLUDED IN THE REPORT
Items 1, 2, 3, 4, 6, 7, 8 and 9 are not applicable and are
omitted from this Report.
Item 5. Other Events
____________
Due to scheduling conflicts with the previously
announced earlier date, the 1999 Annual Meeting of
Stockholders of Duramed Pharmaceuticals, Inc. has
been rescheduled for September 23, 1999. Any
stockholder desiring to submit a proposal under
Securities and Exchange Commission Rule 14a-4(c)
for consideration at the 1999 Annual Meeting
must notify Duramed no earlier than April 30, 1999
and no later than May 30, 1999. The March 31, 1999
deadline for stockholder proposals under SEC Rule
14a-8 (set forth in Duramed's Proxy Statement for
its 1998 Annual Meeting) remains unchanged.
SIGNATURES
__________
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
Date: April 13, 1999 DURAMED PHARMACEUTICALS, INC.
By /s/ Timothy J. Holt
______________________________
Timothy J. Holt
Senior Vice President-Finance
and Administration